Combination of a Latency-Reversing Agent With a Smac Mimetic Minimizes Secondary HIV-1 Infection in vitro
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combination of a Latency-Reversing Agent With a Smac Mimetic Minimizes Secondary HIV-1 Infection in vitro
Authors
Keywords
-
Journal
Frontiers in Microbiology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-09-19
DOI
10.3389/fmicb.2018.02022
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- HIV Latency: Should We Shock or Lock?
- (2017) Gilles Darcis et al. TRENDS IN IMMUNOLOGY
- A clue to unprecedented strategy to HIV eradication: “Lock-in and apoptosis”
- (2017) Hiroshi Tateishi et al. Scientific Reports
- Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy
- (2016) Carolina Gutiérrez et al. AIDS
- The mTOR Complex Controls HIV Latency
- (2016) Emilie Besnard et al. Cell Host & Microbe
- Which therapeutic strategy will achieve a cure for HIV-1?
- (2016) Anthony R Cillo et al. Current Opinion in Virology
- Ex VivoBioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4+T Cells from Aviremic Patients
- (2015) Adam M. Spivak et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Inhibition of HIV-1 entry by the tricyclic coumarin GUT-70 through the modification of membrane fluidity
- (2015) Kouki Matsuda et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- BIRC2/cIAP1 Is a Negative Regulator of HIV-1 Transcription and Can Be Targeted by Smac Mimetics to Promote Reversal of Viral Latency
- (2015) Lars Pache et al. Cell Host & Microbe
- 4′-modified nucleoside analogs: Potent inhibitors active against entecavir-resistant hepatitis B virus
- (2015) Yuki Takamatsu et al. HEPATOLOGY
- Ex vivo analysis identifies effective HIV-1 latency–reversing drug combinations
- (2015) Gregory M. Laird et al. JOURNAL OF CLINICAL INVESTIGATION
- Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis
- (2015) Gregor Ebert et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Apoptosis-induced activation of HIV-1 in latently infected cell lines
- (2015) Sohrab Z. Khan et al. Retrovirology
- Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation
- (2015) Guochun Jiang et al. PLoS Pathogens
- Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study
- (2015) Julian H Elliott et al. Lancet HIV
- TIPE2 inhibits TNF-α-induced hepatocellular carcinoma cell metastasis via Erk1/2 downregulation and NF-κB activation
- (2014) YUE HUA ZHANG et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Birinapant, a Smac-Mimetic with Improved Tolerability for the Treatment of Solid Tumors and Hematological Malignancies
- (2014) Stephen M. Condon et al. JOURNAL OF MEDICINAL CHEMISTRY
- Synergistic Targeting of AML Stem/Progenitor Cells With IAP Antagonist Birinapant and Demethylating Agents
- (2014) Bing Z. Carter et al. JNCI-Journal of the National Cancer Institute
- Birinapant (TL32711), a Bivalent SMAC Mimetic, Targets TRAF2-Associated cIAPs, Abrogates TNF-Induced NF- B Activation, and Is Active in Patient-Derived Xenograft Models
- (2014) C. A. Benetatos et al. MOLECULAR CANCER THERAPEUTICS
- New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo
- (2014) C Korin Bullen et al. NATURE MEDICINE
- Small-molecule SMAC mimetics as new cancer therapeutics
- (2014) Longchuan Bai et al. PHARMACOLOGY & THERAPEUTICS
- Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy
- (2014) A. R. Cillo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Screening for noise in gene expression identifies drug synergies
- (2014) R. D. Dar et al. SCIENCE
- Transcriptional control of HIV latency: Cellular signaling pathways, epigenetics, happenstance and the hope for a cure
- (2014) Uri Mbonye et al. VIROLOGY
- Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial
- (2014) Thomas A Rasmussen et al. Lancet HIV
- Delayed emergence of HIV-1 variants resistant to 4’-ethynyl-2-fluoro-2’-deoxyadenosine: comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001
- (2013) Kenji Maeda et al. ANTIVIRAL THERAPY
- The Novel SMAC Mimetic Birinapant Exhibits Potent Activity against Human Melanoma Cells
- (2013) C. Krepler et al. CLINICAL CANCER RESEARCH
- A novel cell-based high-throughput screen for inhibitors of HIV-1 gene expression and budding identifies the cardiac glycosides
- (2013) G. M. Laird et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Cellular and molecular mechanisms involved in the establishment of HIV-1 latency
- (2013) Daniel A Donahue et al. Retrovirology
- Altering cell death pathways as an approach to cure HIV infection
- (2013) A D Badley et al. Cell Death & Disease
- Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism
- (2012) Jennifer L. Allensworth et al. BREAST CANCER RESEARCH AND TREATMENT
- Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
- (2012) N. M. Archin et al. NATURE
- Targeting IAP proteins for therapeutic intervention in cancer
- (2012) Simone Fulda et al. NATURE REVIEWS DRUG DISCOVERY
- Curing HIV: Pharmacologic Approaches to Target HIV-1 Latency
- (2011) Shailesh K. Choudhary et al. Annual Review of Pharmacology and Toxicology
- The regulation of TNF signalling: what a tangled web we weave
- (2011) John Silke CURRENT OPINION IN IMMUNOLOGY
- Identification of the MMS22L-TONSL Complex that Promotes Homologous Recombination
- (2010) Eris Duro et al. MOLECULAR CELL
- The molecular biology of HIV latency: breaking and restoring the Tat-dependent transcriptional circuit
- (2010) Jonathan Karn Current Opinion in HIV and AIDS
- Potent Activity of a Nucleoside Reverse Transcriptase Inhibitor, 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine, against Human Immunodeficiency Virus Type 1 Infection in a Model Using Human Peripheral Blood Mononuclear Cell-Transplanted NOD/SCID Janus Kinase 3 Knockout Mice
- (2009) S. Hattori et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation
- (2009) Hung-Chih Yang et al. JOURNAL OF CLINICAL INVESTIGATION
- 2′-Deoxy-4′-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants
- (2008) Atsushi Kawamoto et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started